RT Journal Article
SR Electronic
T1 Temporal stability of feno measurement in COPD
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA3994
DO 10.1183/13993003.congress-2015.PA3994
VO 46
IS suppl 59
A1 Bernardino Alcázar Navarrete
A1 Pedro J. Romero Palacios
A1 Francisca Castellano Miñán
A1 Oliverio Ruiz Rodriguez
A1 Andres Ruiz Sancho
YR 2015
UL http://erj.ersjournals.com/content/46/suppl_59/PA3994.abstract
AB Introduction: FeNO measurement colud be a good marker of ACOS, with an optimal cut-off point of 20 ppb. Nevertheless, it´s not been studied the temporal stability of this biomarker in COPD and its prognostic impact.Material & Methods: this is an observational, 1-year follow up, propspective study, which recruited patients with COPD attended in an ambulatory setting. For each patient, data regarding PFTs, CAT questionnaire, blood test and FeNO at 50 mL/s (HypAir FeNO®, Medisoft) were collected. Continous variables are expressed as mean ± SD, and dichotomous variables expressed as absolute and relative frequencies. For all the statistical analysis, a value of p<0,5 was considered as statitistical significant.Results: 122 patients with COPD were included, of whom 113 completed the follow up period. Patients characteristics were: sex male (88,5%), active smokers (27,9%), 70,8 (±10,1) years old, and FEV1 56,5 ± 17,1% predicted. 58,2% were on inhaled corticosteroids, and ACOS patients represented 22,1% of the whole sample. Patients with ACOS showed statistically significant differences in the number of visits with FeNO levels>20 ppb (70,3% of visits vs 16,3% of the non-ACOS COPD patients, p<0,0001). Patients with 2 o more visits with FeNO>20 ppb showed greater moderate and severe exacerbation rates than those without visits with FeNO>20 ppb (1,42 vs 0,67; p=0,009), as well as greater severe exacerbation rates (0,23 vs 0,07; p=0,049).Conclussions: FeNO is a stable biomarker in COPD over the time, specially in patients with ACOS. Persisten high levels are associated with a greater risk of moderate and severe exacerbation rates.